Vertiv Holdings Co (BMV:VRT)
Mexico · Delayed Price · Currency is MXN 2,675.00
-79.54 (-2.89%)
At close: Aug 1, 2025, 2:00 PM CST
Sage Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 9,094 | 8,012 | 6,863 | 5,692 | 4,998 | 4,371 | Upgrade | |
Revenue Growth (YoY) | 26.31% | 16.74% | 20.59% | 13.87% | 14.36% | -1.37% | Upgrade |
Cost of Revenue | 5,884 | 5,078 | 4,463 | 4,075 | 3,475 | 2,897 | Upgrade |
Gross Profit | 3,210 | 2,934 | 2,401 | 1,616 | 1,523 | 1,474 | Upgrade |
Selling, General & Admin | 1,438 | 1,374 | 1,312 | 1,178 | 1,109 | 1,008 | Upgrade |
Other Operating Expenses | 0.6 | -8.5 | -10.7 | -5.4 | -3.8 | 1.5 | Upgrade |
Operating Expenses | 1,624 | 1,550 | 1,483 | 1,389 | 1,250 | 1,139 | Upgrade |
Operating Income | 1,586 | 1,385 | 917.6 | 227.4 | 273.2 | 335.1 | Upgrade |
Interest Expense | -113.2 | -150.4 | -180.1 | -147.3 | -90.6 | -129.1 | Upgrade |
Currency Exchange Gain (Loss) | -13.3 | -11.8 | -16.8 | -3.3 | -3.2 | -26 | Upgrade |
Other Non Operating Income (Expenses) | -247.2 | -449.2 | -157.9 | 90.9 | -2.7 | -165 | Upgrade |
EBT Excluding Unusual Items | 1,212 | 773.1 | 562.8 | 167.7 | 176.7 | 15 | Upgrade |
Merger & Restructuring Charges | -10.5 | -5.3 | -28.6 | -0.7 | -1.4 | -82.6 | Upgrade |
Asset Writedown | - | - | - | - | -8.7 | -13 | Upgrade |
Other Unusual Items | -1.3 | -2.4 | -0.5 | - | -0.4 | -174 | Upgrade |
Pretax Income | 1,200 | 765.4 | 533.7 | 167 | 166.2 | -254.6 | Upgrade |
Income Tax Expense | 387.9 | 269.6 | 73.5 | 90.4 | 46.6 | 72.7 | Upgrade |
Earnings From Continuing Operations | 812.3 | 495.8 | 460.2 | 76.6 | 119.6 | -327.3 | Upgrade |
Net Income | 812.3 | 495.8 | 460.2 | 76.6 | 119.6 | -327.3 | Upgrade |
Net Income to Common | 812.3 | 495.8 | 460.2 | 76.6 | 119.6 | -327.3 | Upgrade |
Net Income Growth | 62.82% | 7.74% | 500.78% | -35.95% | - | - | Upgrade |
Shares Outstanding (Basic) | 379 | 376 | 380 | 377 | 356 | 307 | Upgrade |
Shares Outstanding (Diluted) | 388 | 386 | 386 | 378 | 360 | 307 | Upgrade |
Shares Change (YoY) | -0.35% | 0.03% | 2.12% | 5.02% | 17.28% | 159.66% | Upgrade |
EPS (Basic) | 2.15 | 1.32 | 1.21 | 0.20 | 0.34 | -1.07 | Upgrade |
EPS (Diluted) | 2.09 | 1.28 | 1.19 | -0.04 | 0.33 | -1.07 | Upgrade |
EPS Growth | 64.05% | 7.56% | - | - | - | - | Upgrade |
Free Cash Flow | 1,248 | 1,152 | 772.6 | -252.8 | 137.5 | 164.5 | Upgrade |
Free Cash Flow Per Share | 3.22 | 2.98 | 2.00 | -0.67 | 0.38 | 0.54 | Upgrade |
Dividend Per Share | 0.063 | 0.113 | 0.025 | 0.010 | 0.010 | 0.010 | Upgrade |
Dividend Growth | -16.67% | 350.00% | 150.00% | - | - | - | Upgrade |
Gross Margin | 35.30% | 36.62% | 34.98% | 28.39% | 30.47% | 33.72% | Upgrade |
Operating Margin | 17.44% | 17.28% | 13.37% | 4.00% | 5.47% | 7.67% | Upgrade |
Profit Margin | 8.93% | 6.19% | 6.71% | 1.35% | 2.39% | -7.49% | Upgrade |
Free Cash Flow Margin | 13.72% | 14.38% | 11.26% | -4.44% | 2.75% | 3.76% | Upgrade |
EBITDA | 1,871 | 1,662 | 1,189 | 529.8 | 500.2 | 538.2 | Upgrade |
EBITDA Margin | 20.57% | 20.74% | 17.32% | 9.31% | 10.01% | 12.31% | Upgrade |
D&A For EBITDA | 284.8 | 277 | 271 | 302.4 | 227 | 203.1 | Upgrade |
EBIT | 1,586 | 1,385 | 917.6 | 227.4 | 273.2 | 335.1 | Upgrade |
EBIT Margin | 17.44% | 17.28% | 13.37% | 4.00% | 5.47% | 7.67% | Upgrade |
Effective Tax Rate | 32.32% | 35.22% | 13.77% | 54.13% | 28.04% | - | Upgrade |
Revenue as Reported | 9,094 | 8,012 | 6,863 | 5,692 | 4,998 | 4,371 | Upgrade |
Advertising Expenses | - | 19.4 | 20.1 | 20.6 | 26 | 28.3 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.